Catalyst Pharmaceuticals Inc (CPRX)
23.95
+0.70
(+3.01%)
USD |
NASDAQ |
Nov 08, 11:46
Catalyst Pharmaceuticals Revenue (TTM): 460.48M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 460.48M |
| June 30, 2024 | 434.48M |
| March 31, 2024 | 411.35M |
| December 31, 2023 | 398.20M |
| September 30, 2023 | 348.39M |
| June 30, 2023 | 302.95M |
| March 31, 2023 | 256.48M |
| December 31, 2022 | 214.20M |
| September 30, 2022 | 191.76M |
| June 30, 2022 | 170.46M |
| March 31, 2022 | 153.72M |
| Date | Value |
|---|---|
| December 31, 2021 | 140.83M |
| September 30, 2021 | 133.54M |
| June 30, 2021 | 126.90M |
| March 31, 2021 | 120.14M |
| December 31, 2020 | 119.07M |
| September 30, 2020 | 118.18M |
| June 30, 2020 | 119.76M |
| March 31, 2020 | 118.99M |
| December 31, 2019 | 102.31M |
| September 30, 2019 | 72.68M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
102.31M
Minimum
Dec 2019
460.48M
Maximum
Sep 2024
222.11M
Average
162.09M
Median
Revenue (TTM) Benchmarks
| Sarepta Therapeutics Inc | 1.640B |
| Vertex Pharmaceuticals Inc | 10.63B |
| Regenxbio Inc | 84.33M |
| Edgewise Therapeutics Inc | -- |
| Entrada Therapeutics Inc | 215.23M |